Cancer clinical trials in the region Bourgogne-Franche-Comté

175 currently recruiting clinical trials
Region Bourgogne-Franche-Comté

Early Access Lymphoma
B cell lymphoma Large B cell lymphoma 2 3 or more
Systemic Treatment-Naive
Hoffmann-La Roche
Early Access Lung cancer
SCLC (Small Cell Lung Cancer) Localized Locally Advanced None Chemotherapy Radiotherapy Chemotherapy Radiotherapy
AstraZeneca
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR None Systemic Treatment-Naive
Janssen
Early Access Lung cancer
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic EGFR 1 Targeted therapy
Systemic Treatment-Naive
Janssen
Early Access Lymphoma
B cell lymphoma Large B cell lymphoma 1
Systemic Treatment-Naive
Hoffmann-La Roche
Phase 3 Anal cancer #NCT06207981 #2023-505972-32-00
Locally Advanced
Radiotherapy Radiotherapy
Institut de Cancérologie de Bourgogne - Site de Dijon (Dijon), Hôpital Le Bocage (Dijon), Hôpital Privé Sainte Marie - Ramsay Santé (Chalon-sur-Saône), Centre Hospitalier Universitaire de Besançon (Besançon), Centre Hospitalier d’Auxerre (Auxerre)
Fédération Francophone de Cancérologie Digestive
Phase 3 Breast cancer #NCT05952557 #2023-504031-41-00
HER2 Negative HR Positive Localized None Surgery Chemotherapy Radiotherapy Hormone therapy
Systemic Treatment-Naive
CGFL Dijon - Centre Régional De Lutte Contre Le Cancer Georges - François Leclerc (Dijon )
AstraZeneca
Phase 3 Lymphoma #NCT06006117 #2022-501810-77-00
B cell lymphoma Marginal zone lymphoma None > 60 ml/min 50-60 ml/min 30-50 ml/min 1 2 3 or more Targeted therapy Monoclonal antibodies
Systemic Treatment-Naive Bispecific T-cell engager antibodies Allogeneic stem cell transplant
Centre hospitalier universitaire François Mitterrand (Dijon), Centre Hospitalier Universitaire de Besançon (Besançon)
The Lymphoma Academic Research Organisation (LYSARC)
Phase 3 Lymphoma #NCT04224493 #2024-510690-16-00
B cell lymphoma Follicular lymphoma None > 60 ml/min 50-60 ml/min 30-50 ml/min 1 2 3 or more Chemotherapy Monoclonal antibodies Radiotherapy
Systemic Treatment-Naive
Centre Hospitalier Universitaire de Besançon (Besançon)
Epizyme, Inc. (Ipsen)
Phase 3 Lung cancer #NCT06345729 #2023-507776-42-00
NSCLC (Non-Small Cell Lung Cancer) Locally Advanced Metastatic KRAS G12C PDL1 Positive (>= 50%) None Systemic Treatment-Naive
Centre hospitalier universitaire François Mitterrand (Dijon)
Merck Sharp & Dohme LLC